Advances in treating psoriasis in the elderly with small molecule inhibitors.

about

Advances in treating psoriasis in the elderly with small molecule inhibitors.

Item

http://www.wikidata.org/entity/Q49679446

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Advances in treating psoriasis in the elderly with small molecule inhibitors.

@en

Advances in treating psoriasis in the elderly with small molecule inhibitors.

@nl

type

Item

label

Advances in treating psoriasis in the elderly with small molecule inhibitors.

@en

Advances in treating psoriasis in the elderly with small molecule inhibitors.

@nl

prefLabel

Advances in treating psoriasis in the elderly with small molecule inhibitors.

@en

Advances in treating psoriasis in the elderly with small molecule inhibitors.

@nl

P1476

Advances in treating psoriasis in the elderly with small molecule inhibitors

@en

P2093

Leah A Cardwell

http://www.w3.org/2001/XMLSchema#string

Steven R Feldman

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic targeting of Janus kinases

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Progress in understanding the immunopathogenesis of psoriasis

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.

The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.

Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use

P304

1965-1973

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1409205

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Abigail Cline

P577

2017-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29171774

http://www.w3.org/2001/XMLSchema#string